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Incident HIV infection has fallen rapidly in
men who have sex with men in Melbourne,
Australia (2013–2017) but not in the newly-
arrived Asian-born
Nicholas A. Medland1,2,3* , Eric P. F. Chow1,2, Timothy H. R. Read1,2, Jason J. Ong1,2,4, Marcus Chen1,2,
Ian Denham1, Praveena Gunaratnum3 and Christopher K. Fairley1,2
Abstract
Background: We examined differences in incident HIV infection between newly-arrived Asian-born and other men
who have sex with men (MSM) after the introduction of universal HIV treatment guidelines in 2015 and pre-
exposure prophylaxis in 2016.
Methods: Clinical, demographic, laboratory and behavioural data on MSM presenting for HIV testing at the
Melbourne Sexual Health Centre from July 2013 to June 2017 were extracted. We compared the proportion of
newly-arrived (four years or less in Australia), Asian-born and other MSM tested each year who were diagnosed with
incident HIV infection (negative test within one year or diagnosis with indeterminate or negative Western Blot).
Results: We analysed 35,743 testing episodes in 12,180 MSM, including 2781 testing episodes in 1047 newly-arrived
Asian-born MSM. The proportion of other MSM tested each year who were diagnosed with incident HIV infection
fell from 0.83% in 2014 to 0.38% in 2017 (p = .001), but did not fall in newly-arrived Asian-born MSM (from 1.18% in
2014 to 1.56% in 2017, p = .76). In the multivariate logistic regression, in 2016/2017 but not in 2014/2015, being
newly-arrived Asian-born was associated with an increased odds of diagnosis of incident HIV infection (aOR 3.29,
95%CI 1.82–5.94, p < .001).
Conclusions: The epidemiology of HIV in Melbourne Australia has changed dramatically. While there has been an
overall reduction amongst MSM, the incidence of HIV in newly-arrived Asian-born MSM remains high. Failing to
address these new inequalities leaves individuals at risk and may offset the population benefit of biomedical HIV
prevention.
Keywords: HIV, Incidence, Treatment as prevention, Pre-exposure prophylaxis, Sexual transmission
Background
The effectiveness of HIV pre-exposure prophylaxis
(PrEP) and treatment as prevention (TasP) in interrupt-
ing HIV transmission is well established [1, 2]. The scale
up of these biomedical prevention modalities is now a
central pillar of the HIV response in high income coun-
tries [3–5]. HIV incidence may already be declining in
urban MSM populations [6]. As with any population
intervention, the maximal population benefit will occur
with high coverage across the highest risk groups [7].
Incomplete coverage of neglected priority populations
may leave individuals at risk and offset the population
benefit. In particular, because biomedical HIV preven-
tion is accessed through health care systems, those with
less access to health care may benefit less.
In Australia, antiretroviral therapy (ART) is publicly
funded and has been available to all patients regardless
of CD4 cell count or clinical stage since 2015 [8]. Since
2016, PrEP has been available through large publicly
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funded projects in major metropolitan centres, including
Melbourne [9, 10]. However, eligibility for Medicare,
Australia’s national universal health insurance scheme, is
required to access antiretroviral therapy nationally and
to access PrEP in Melbourne. Melbourne is a so-called
fast-track city and reports progress against the 90–90-90
goals of 90%, 94% and 93% of people living with HIV
diagnosed, on ART and with virological suppression re-
spectively [11, 12].
The Melbourne Sexual Health Centre (MSHC) in
Victoria, Australia, is a large government funded sexual
health service which provides free HIV and STI screen-
ing to more than 6000 MSM every year and makes more
than a quarter of new HIV diagnoses in MSM in the
state [13–15]. Unlike other parts of the Australian health
care system, sexual health centres are not required to
establish patients’ Medicare eligibility and do not charge
Medicare ineligible patients for STI testing. However,
that funding does not cover the provision of ART or
PrEP.
We chose newly-arrived Asian-born MSM as a sub-
population of interest for several reasons. Each year
Australia, a country of 24 million people, admits 700,000
temporary migrants (excluding tourists and including
approximately 250,000 working holiday makers under
30 years of age) plus more than 700,000 international
students [16]. Students from China, India, Nepal, Malaysia
and Vietnam make up 53% of the latter group [16]. With
some exceptions, temporary migrants and international
students are not eligible for Medicare and cannot access
publicly funded for ART or PrEP, at least in the state of
Victoria [17]. Asian-born MSM may have poorer know-
ledge of HIV and sexual health or be less successful nego-
tiating risk reduction strategies [18].
This study aims to examine whether there is any
difference in the incidence of HIV infection between
newly-arrived (i.e. within 4 years) Asian-born and the
other MSM and if this has changed since the introduc-
tion of of treat-all ART guidelines in 2015 and the wide-
spread availability of PrEP in 2016.
Methods
We undertook a retrospective observational study by
reviewing the records of MSM tested for HIV between
July 1st 2013 and June 30th 2017 at MSHC. We in-
cluded all HIV testing episodes in males of 18 years of
age or greater who reported having had sexual contact
with other males in the last 12 months. We excluded
any testing episode in a patient who had previously
received a positive HIV test, including those referred to
the centre having recently been tested elsewhere, and
also excluded any testing episode in which no date of
previous negative HIV test was available, including those
presenting for their first test. Patients presenting for care
at the MSHC specialist HIV treatment services and pa-
tients attending the dedicated clinic for PrEP were not
included.
MSHC uses a customised electronic medical record
(Clinical Patient Management System, CPMS) which
collects demographic, sexual behavioral and clinical
information on all patients. All patients complete a self-
administered computer-assisted self-interview (CASI) on
sexual history such as number and gender of sexual part-
ners, condom use and prior HIV testing. The Melbourne
Diagnostic Unit Public Health Laboratory (MDU, Univer-
sity of Melbourne) provides onsite laboratory services for
microbiological specimens for Neisseria gonorrhoeae (nu-
cleic acid amplification testing (NAAT) and culture) and
Chlamydia trachomatis (NAAT). The Victorian Infectious
Diseases Reference Laboratory (VIDRL) is contracted to
perform all off-site laboratory testing including HIV and
syphilis serology.
We extracted the following data from the consultation
record at which the HIV testing was performed: age,
gender, country of birth, year of arrival in Australia,
number and gender of sexual partners and condom use
in the past 3 months, the date and result of the most
recent previous HIV test, if the patient was taking PrEP
(recorded from March 2016), symptoms of STI, a new
diagnosis of early syphilis. Data provided from MDU
included results of testing for gonorrhoea and chlamydia
performed at that consultation. Data provided by VIDRL
included HIV testing results and prior HIV testing
results and syphilis serology. HIV test results were col-
lected from January 1st 2011 so that the inter-test period
could be calculated in the vast majority of patients.
Following Australian guidelines, HIV is diagnosed using
a two step algorithm: a screening assay which, if reactive,
is followed by a confirmatory Western Blot assay [19, 20].
Until April 29th 2014 the screening assay was the Abbott
Murex HIV-1 2.0 EIA (3rd generation). After that date the
DiaSorin Liaison XL Murex HIV Ab/Ag CLIA (4th gener-
ation) assay was used as the screening assay. The MP
Diagnostics HIV1/2 Blot 2.0 Western Blot assay was used
as the confirmatory test for the entire study period. For
this study, the Western Blot was recorded as positive if
there were one or more glycoprotein bands and three or
more viral protein specific bands. We recorded the result
as indeterminate if specific viral bands were present but
the above criteria for a positive result were not met. If no
viral specific bands were present the assay was recorded
as negative.
We defined incident HIV infection as confirmed HIV
infection with either a recorded previous HIV test within
the past 365 days or serological evidence of recent infec-
tion (a reactive screening test and a negative or indeter-
minate Western blot) [21, 22]. To accommodate testing
at multiple locations, the date of previous negative HIV
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test used in the analysis was the most recent of the date
recorded in the clinical record on the day of the test and
the date of the most recent test performed at MSHC, as
has been previously published [22].
Patients were categorized as Asian-born if they were
born in the following South, East and Southeast Asian
countries: Bangladesh, Bhutan, Brunei, Cambodia, China,
East Timor, Hong Kong, India, Indonesia, Japan, North
Korea, South Korea, Laos, Macau, Malaysia, Maldives,
Mongolia, Myanmar, Nepal, Pakistan, Philippines,
Singapore, Sri Lanka, Taiwan, Thailand or Vietnam. Pa-
tients were categorized as newly-arrived if the year of ar-
rival in Australia was 4 years or less before the year of the
HIV test. Those that met these criteria on the day of the
HIV test were classified as newly-arrived Asian-born MSM.
Study periods were the year from July 1st 2013 until
June 30th 2014 (hereafter referred to as 2014) and then
the year to June 30th 2015, 2016 and 2017 respectively
(hereafter referred to as 2015, 2016, 2017). Each study
period was exactly one calendar year.
Our primary outcome measure was the proportion of
MSM tested each year (2014–2017) who were diagnosed
with incident HIV infection. The secondary outcome
measure was the proportion of individuals tested each
year who were diagnosed HIV positive. For a supple-
mentary analysis to support the choice of study popula-
tion stratification, we performed analysis of the primary
outcome measure in the following population subgroups
using the definitions above: newly-arrived Asian-born
MSM, newly-arrived not Asian-born MSM and Asian-
born not newly-arrived MSM and compared them to
MSM not in that subgroup.
Our hypothesis was that a difference between popula-
tion subgroups would emerge with the introduction of
biomedical HIV prevention. Factors that were associated
with the odds of diagnosis of incident HIV were exam-
ined using logistic regression performed using general-
ized estimating equation (GEE) models for repeated
measures in individuals. The analysis was performed
twice covering testing during two time periods: 01 July
2013 to 30 June 2015 and 1 July 2015 to 30 June 2017.
We examined the following co-variates in each: age,
country of birth (Australia, Organisation for Econonic
Development (OECD) member country, Asia as defined
above), new arrival in Australia (year of arrival less than
4 years before the year of the test), being newly-arrived
Asian-born, time since prior HIV test, reporting consist-
ent condom use (or no anal sexual partners) in the pre-
vious 3 months, reporting ten or more sexual partners
in the previous 3 months, presentation with symptoms
of a sexually transmitted infection on the day of the test,
a diagnosis of secondary or recently acquired syphilis,
pharyngeal, urethral or anorectal gonorrhea, or urethral
or anorectal chlamydia. Covariates associated with the
outcome with a p value less then.20 were included in the
multivariate analysis. Newly-arrived Asian-born status
was entered in the multivariate analysis in both models.
All analyses were conducted using the STATA Statistics
software package (version 14). This study was approved by
the Alfred Hospital Ethics Committee (approval number
335/17). This study is reported in accordance with
STROBE and RECORD statements [23, 24].
Results
We included 2781 HIV tests in 1047 newly-arrived
Asian-born men who have sex with men (MSM) and
32,962 HIV tests in 11,133 other MSM performed be-
tween 1 July 2013 and 30 June 2017 after excluding first
tests in 825 newly-arrived Asian born MSM and 2051
other MSM with no record of prior testing. Compared
to other MSM, newly-arrived Asian-born MSM were
younger (median 26.4 vs 29.5 years of age, p < .0001),
had a shorter interval between HIV tests (median 109 vs
133 days, p < .0001), were less likely to present with
symptoms (16.8% vs 22%, p < .001). They were more
likely to report consistent condom use and less than ten
sexual partners in the previous 3 months. Despite this,
these individuals were more than twice as likely to be
diagnosed HIV positive (3.53% vs 1.56%, p < .001) or
with incident HIV infection (2.42% vs 1.13%, p < .001).
See Table 1.
In study year 2014 there was no significant difference
in consistent condom use reported between the two
groups (57.4% in newly-arrived Asian-born MSM vs
53.4% in other MSM in study year 2014 p = .12), but it
fell in both groups during the study. The fall was greater
in other MSM so that by the end of the study period a
greater proportion of newly-arrived Asian-born MSM
were reporting consistent condom use (51.9% vs 38.2%
p < .001). Newly-arrived Asian-born MSM were less
likely to report 10 partners or more in the previous
3 months in all study periods with no significant change
in either group over the study period. In study year
2014, newly-arrived MSM were more likely to be diag-
nosed with anorectal chlamydia (7.58% vs 4.84%, p
= .014). However, during the study, anorectal chlamydia
increased in other MSM but not in newly-arrived
Asian-born MSM, so that by 2017 there was no signifi-
cant difference between the two groups (7.82% of
newly-arrived Asian-born MSM presentations vs 7.07%
other MSM, p = .35). In 2017, newly-arrived Asian-born
MSM were less likely to be taking PrEP (6.8% vs 11.1%,
p < .001). See Table 2.
In the first two study years (2014–2015), there was no
significant difference between newly-arrived Asian-born
and other MSM in the proportion tested each year who
were diagnosed with incident HIV infection. However,
in the final two study years (2016–2017) a difference
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emerged and the proportion of newly-arrived Asian-
born MSM tested each year who were diagnosed with
incident HIV infection was significantly higher than
in other MSM. By study year 2017, the proportion of
newly-arrived Asian-born MSM diagnosed with inci-
dent HIV infection was more than four times other
MSM (1.56% vs 0.38% p < .001). There was a statisti-
cally significant downward trend in other MSM (from
0.83% in 2014 to 0.38% in 2017, ptrend = .001). How-
ever, the proportion of newly-arrived Asian-born
MSM tested each year who were diagnosed with
incident HIV infection did not change significantly
during the study period (from 1.18% in 2014 to 1.56%
in 2017, p = .76) See Table 2 and Fig. 1.
In the first two study years (2014–2015), there was no
significant difference between newly-arrived Asian-born
and other MSM in the proportion of individuals tested
each year who were diagnosed HIV positive. However, in
the final two study years (2016–2017) a difference emerged
and the proportion of newly-arrived Asian-born MSM
tested each year who were diagnosed HIV positive and it
was significantly higher than in other MSM. By 2017, the
Table 1 Characteristics of men who have sex with men (MSM) undergoing HIV testing at Melbourne Sexual Health Centre
(Australia) from July 1st 2013 until June 30th 2017
Other MSM Newly arrived Asian born MSM1 P value
Number of people tested 11,1332 10474
Number of testing episodes5 32,962 2781
Age, years median (IQR) 29.5 (25.0–37.0) 26.4 (23.5–29.8) <.0001§
Born in Australia, n (%) 6723 (60.4%) – –
Born OECD Country6 8727 (78.4%) 58 (5.54%) <.001¶
Born S, E or SE Asia7 1331 (12.0%) –
Newly Arrived2 1846 (16.6%) –
Days since prior test, median (IQR) 133 (78–273) 109 (63–214) <.0001§
Symptoms8, n (%) 7260 (22.0%) 466 (16.8%) <.001¶
Syphilis8, n (%) 515 (1.56%) 44 (1.58%) .94¶
Pharyngeal gonorrhoea8, n (%) 468 (1.42%) 23 (0.83%) .01¶
Urethral gonorrhoea 8, n (%) 774 (2.35%) 43 (1.55%) .007¶
Urethral chlamydia 8, n (%) 897 (2.72%) 62 (2.23%) .12¶
Anal gonorrhoea8, n (%) 1508 (4.57%) 130 (4.67%) .81¶
Anal chlamydia8, n (%) 1991 (6.04%) 224 (8.05%) <.001¶
Consistent condom use8, n (%) 13,975 (46.3%) 1357 (53.9%) <.001¶
10 or more partners in 3 months8 n (%) 4501 (13.7%) 233 (8.4%) <.001¶
Positive HIV tests, n 175 36
% of tests performed9 0.53 1.29 <.001¶
% of people tested10 1.56% 3.53% <.001¶
Incident HIV, n11 126 24
% positive tests12 72.0% 66.7% .52¶
% tests performed9 0.38 0.87 <.001¶
% of people tested10 1.13% 2.42% <.001¶
1. Defined as year of arrival in Australia 4 years or less than the year of the HIV test and country of birth one of 26 Eastern, Southern and South-eastern
Asian countries
2. Number of individuals who did not meet criteria at any time during the study
4. Number of individuals who met the criteria at any time during the study period
5. Number of tests in people meeting criteria at the time of the test
6. Country of birth given as one of 35 member countries of the Organisation for Economic Development
7. Country of birth given as one of 26 southern, eastern or South-eastern Asian countries
8. Testing episodes
9. Proportion of all included HIV tests performed during the study period
10. Proportion of all included individuals tested during the study period
11. Reported negative HIV test within 1 year or serological evidence of recent infection
12. Proportion of all positives tests which were acute or early
¶ = chi squared
§ Wilcoxon rank-sum (Mann-Whitney) test
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proportion of newly-arrived Asian-born MSM tested each
year who were diagnosed HIV positive was more than
three times other MSM (2.41% vs 0.68%, p < .001). There
was a statistically significant downward trend in other
MSM (from 1.20% in 2014 to 0.68% in 2017, p = .02). How-
ever, the proportion of newly-arrived Asian-born MSM
tested each year who were diagnosed HIV positive did not
change significantly during the study period (from 1.57% in
2014 to 2.41% in 2017, p = .53) See Table 2.
For the supplementary analysis, in study years 2014
and 2015, we found that there was no statistically signifi-
cant difference in the proportion tested each year who
were diagnosed with incident HIV infection in the fol-
lowing subgroups when compared to the rest of the
MSM population excluding that subgroup: newly-arrived
Asian-born MSM, Asian-born not newly-arrived MSM,
newly-arrived not Asian-born MSM and not newly-arrived
not Asian-born MSM. By study year 2017, only the
newly-arrived Asian-born subgroup was statistically signifi-
cantly different from the remaining MSM community. See
Additional file 1: Table S1 and Additional file 2: Figure S1.
Being newly-arrived and Asian-born was associated in
the multivariate analysis with the odds of being diag-
nosed with incident HIV infection in the period July
2015–June 2017 (aOR 4.40 (2.38–8.15), p < .001)) but
not in the period July 2013–June 2015. Consistent con-
dom use and number of sexual partners greater than ten
was associated in the earlier time period but not in the
later time period. See Table 3.
Discussion
This study reports the proportion of MSM tested each
year who are diagnosed with incident HIV infection at a
public sexual health service in Melbourne, Australia
from 2013 to 2017 and finds that a difference emerged
between newly-arrived Asian-born and other MSM. The
proportion tested each year diagnosed with incident HIV
infection fell significantly in other MSM but not in
newly-arrived Asian-born MSM. Our findings suggest
that there was a change in risk factors for incident HIV
infection among MSM in Melbourne over the study
period. In the beginning of the study period there was
no statistically significant difference between the two
groups, but by the end of the study period newly-arrived
Asian-born MSM were more than four times more likely
to be diagnosed with incident HIV infection (1.56% vs
0.38%, p < .001). The disappearance of condom use and
number of partners in later years as a risk factor for inci-
dent HIV suggests that limited access to biomedical
interventions in newly-arrived Asian-born MSM is
explaining the observed disparity in HIV incidence.
A recently published study of HIV testing in MSM in
inner London reports a declining proportion of positive
tests from late 2015 to late 2017 which they attribute to
early diagnosis, early initiation of treatment and uptake
of PrEP, that is biomedical rather than behavioural pre-
vention [6]. Melbourne is a so-called fast-track city and
reports progress in excess of 90–90-90 targets [11, 12].
The probability of acquisition of HIV infection is re-
lated to the frequency of exposure, the per-exposure
probability of transmission and the prevalence of unsup-
pressed HIV infection in sexual partners. We examined
incident HIV infection of less than 1 year duration and
therefore assume that the majority of HIV infections in-
cluded in this study were locally acquired. In this study,
newly-arrived Asian-born MSM report less sexual part-
ners and more consistent condom use than other MSM
who experienced a falling rate of diagnosis of incident
HIV infection despite falling condom use. This suggests
a change in vulnerability to HIV infection despite sexual
behavior as measured on these indices. Although newly-
arrived Asian-born MSM were less likely to report tak-
ing PrEP than others, the magnitude of the difference
and the overall proportion taking PrEP (6.8% vs 11,1% in
2017 p < .001) would not suggest that PrEP use is an ex-
planation for the four-fold difference in incident HIV
diagnoses.
Available evidence points toward a substantial decline
in the prevalence of unsuppressed HIV infection in Mel-
bourne over the study period. With earlier diagnosis and
initiation of antiretroviral therapy, the infectious period
between infection and virological suppression has fallen
more than five-fold [22]. The magnitude and the timing
of these changes could certainly explain the reduction in
incident HIV infection in MSM in Melbourne.
Assortative sexual mixing patterns are of increasing
interest in HIV transmission research [25]. Our findings
could, at least in part, be explained if newly-arrived
Asian-born MSM were more likely to have newly-arrived
Asian-born MSM as sexual partners and had a higher
prevalence of unsuppressed HIV infection. Newly-arrived
Asian-born MSM who are overseas students, working
holiday makers or temporary migrants will not be eligible
for Medicare or publicly funded ART. There is evidence
to suggest that individuals born overseas may be less likely
to be offered or less likely to initiate early antiretroviral
therapy [26, 27]. At our centre, MSM couples have been
studied in STI transmission studies [28]. Of MSM couples
studied at MSHC, 10 of 42 (24%) newly-arrived Asian
born MSM and 30 of 685 other MSM (4.4%) reported be-
ing in a relationship with a newly-arrived Asian-born MSM
(EPF Chow personal communication: unpublished).
Once diagnosed with HIV infection at Melbourne
Sexual Health Centre, patients who are ineligible for
Medicare are able to access medical services free of
charge including antiretroviral therapy, which is pro-
vided through private compassionate access programs
supported by the pharmaceutical industry. A recent
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analysis at this centre showed that country of birth and
recent arrival in Australia were not associated with de-
layed HIV diagnosis or virological suppression after
diagnosis [22]. However, this centre is the only publicly
funded sexual health centre that is able to offer these
services free of charge in a city with a population of
approximately five million people and with a large but
unknown number of newly-arrived Asian born MSM.
Therefore, it is possible that most newly-arrived Asian-
born MSM who are infected with HIV are not patients
of MSHC. Newly-arrived Asian-born MSM who are not
engaged in care at a publicly funded sexual health centre
(that provides sexual health and HIV medicine services
free of charge) may be more likely to experience a de-
layed diagnosis or virological suppression after diagnosis.
In fact, delayed HIV diagnosis and virological suppres-
sion in newly-arrived Asian-born MSM who are not
engaged in care at publicly funded sexual health centres
may explain the difference in risk of HIV acquisition
observed in this study. The prevalence of undiagnosed
and untreated HIV infection (where HIV transmission
to others may occur) may be higher in this group than
in those with better health care access. Because of sexual
mixing patterns, newly-arrived Asian-born MSM may be
more likely to have sexual partners who are their peers,
that is with peers with are able to transmit HIV infection
to others. Sexual mixing patterns and restricted access
to HIV testing, HIV treatment and PrEP may explain
the large difference in proportion who are diagnosed
with incident HIV infection that was observed in this
study.
Furthermore, little is known about newly-arrived
Asian-born MSM as a population: the size of the popu-
lation, their sexual behavior, their perception or know-
ledge of risk of sexually transmitted infections including
HIV or how to reduce that risk, how differential health
care access might affect outcomes in other areas of
health. Rising epidemics of HIV in MSM communities
in Asia are increasingly described, including in mainland
China [29]. It is not known to what extent these epi-
demics are connected to HIV transmission amongst
newly-arrived Asian-born MSM in Australia.
In this study, we have focused on health care access
issues due to their pertinence to biomedical HIV preven-
tion. However, additional research is required to identify
and target other vulnerabilities that may place this group
at increased risk, which may include language, culture,
gay community engagement, sources of HIV informa-
tion, sexual experience and ability to negotiate successful
risk reduction strategies.
Our study is subject to certain limitations. Firstly, the
primary outcome measure of our study, the proportion
tested each year who are diagnosed with incident HIV
infection, is not a direct measure of incidence and may
underestimate it. However, the short testing intervals in
the study population would suggest that in this popula-
tion of MSM undergoing frequent retesting that this
measure is closely linked to incidence and that there
Fig. 1 Proportion of individuals tested in each year who are diagnosed with incident HIV infection (2014–2017)
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would not be a larger underestimation in other MSM
than the newly-arrived Asian born MSM. The large dif-
ference in the outcome measure and the small difference
in testing frequency between the groups means that a
difference in HIV incidence is most probable reason for
the observed difference. Secondly, MSM attending
MSHC may not be representative of MSM in Victoria.
Because patients who are ineligible for Medicare are
able to access care free of charge, we would expect
newly-arrived Asian-born MSM to be over-represented
amongst MSHC patients, making it a useful site for study
of this group. Also, because of ease of access at this site, it
may be MSM attending MSHC have more frequent HIV
testing.
In the era of biomedical HIV prevention, to maximize
the success of these costly interventions at the popula-
tion level, obstacles and barriers to access must be mini-
mized. In Australia, with a highly accessibly universal
health care system we have observed that while incident
HIV is declining in most MSM, a subpopulation with
less access to health care is still experiencing high inci-
dence. Based on this, it is recommended that provision
of sexual health and HIV medicine services free of
charge, including HIV testing, antiretroviral therapy and
preexposure prophylaxis is expanded to cover patients
who are not eligible for Medicare. Preventable HIV in-
fections are serious in any subpopulation, but many
newly arrived Asian-born MSM will eventually return to
countries with poorer protection and services for people
living with HIV and may experience stigma, discrimin-
ation and poorer health outcomes.
Such intervention would come with considerable costs
given that these services are not subsidised by Medicare.
However, having a certain subpopulation with higher
rates of HIV transmission and lower rates of testing
and treatment will undermine the population effect of
biomedical HIV prevention and reduce the return-on-
investment for treatment as prevention and pre-ex-
posure prophylaxis. This core group of undiagnosed
infections will allow HIV to be sustained in the popu-
lation as they are responsible for a disproportionate
amount of transmissions. Hence the benefit of provid-
ing services to this group may outweigh the costs.
International students bring more than $20 billion into
Australia each year and represent a larger source of for-
eign income than mining exports [30]. Temporary mi-
grants and international students make up a significant
proportion of the population of young sexually active
Table 3 Logistic regression analysis, using generalized estimating equations for multiple observations in individuals, on odds of
being diagnosed with incident HIV infection in the time period 1 July 2013 to 30 June 2015 and 1 July 2015 to 30 June 2017
July 2013–June 2015 July 2015–June 2017
OR1 p aOR2 p OR1 p aOR2 p
Age years3 0.77 (0.60–0.98) .036 0.93 (0.72–1.20) .56 0.8 (0.68–1.12) .27
Not newly-arrived not Asian-born ref ref
Newly-arrived Asian-born 1.79 (0.85–3.79) .13 1.51 (0.63–3.62) .36 3.92 (2.14–7.18) <.001 4.40 (2.38–8.15) <.001
Asian-born not newly arrived 1.06 (0.53–2.09) .88 2.43 (1.31–4.51) .005 2.63 (1.41–4.93) .002
Newly-arrived not Asian-born 1.44 (0.77–2.71) .26 1.52 (0.70–3.31) .29
Months since prior test 0.97 (0.94–1.00) .054 0.98 (0.95–1.01) .12 0.99 (0.96–1.01) .35
Symptoms n (%)7 1.79 (1.13–2.84) .013 1.41 (0.84–2.36) .80 1.37 (0.80–2.34) .25
Syphilis n (%)7 1.83 (0.45–7.49) .40 5.72 (2.46–13.3) <.001 4.01 (1.68–9.55) .002
Pharyngeal gonorrhoea7 1.89 (0.59–6.01) .28 1.57 (0.22–11.4) .65
Urethral gonorrhoea7 2.80 (1.13–6.97) .027 0.86 (0.28–2.63) .80 1.33 (0.36–5.44) .69
Urethral chlamydia7 2.05 (0.75–5.63) .16 1.30 (0.44–3.79) .63 1.05 (0.26–4.28) .95
Anal gonorrhoea7 9.41 (5.58–15.9) <.001 5.97 (3.25–10.97) <.001 4.09 (2.23–7.49) <.001 2.97 (1.57–5.63) .001
Anal chlamydia7 4.70 (2.67–8.27) <.001 2.46 (1.28–4.73) .007 2.70 (1.45–5.03) .002 1.69 (0.87–3.27) .12
100% condom use8 0.43 (2.67–8.27) .001 0.55 (0.33–0.91) .019 0.57 (0.34–0.95) .032 0.65 (0.39–1.11) .12
10 or more partners in 3 months9 2.46 (1.50–4.03) <.001 2.05 (1.21–3.46) .007 2.09 (1.21–3.62) .008 1.80 (1.02–3.17) .04
1. Odds ratio
2. adjusted Odds Ratio
3. Odds ratio per 10 year increment in age
4. Reference group is the rest of the population who is, respectively, not born in Australia, not born in OECD country, not nearly arrived Asian born, not Asian born
or not newly arrived
5. Newly-arrived Asian-born was entered in the multivariate analysis instead of separately entering newly-arrived and Asian-born
7. Reference group is the rest of the population/tests who, respectively, did not present with symptoms, were not diagnosed with syphilis, urethral STI or
anorectal STI
8. Reports always using condoms in anal sex, or no anal sex, or no sexual partners in past three months. Reference group is those with inconsistent condom use
9. Reference group is those not reporting 10 or more sexual partners in past three months
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adults and withholding the benefits for accessing PrEP
and TasP from them may be an Achilles’ heel of the bio-
medical prevention approach.
Conclusion
The epidemiology of HIV in MSM has changed since
the introduction of universal HIV treatment recommen-
dations and PrEP and incident HIV infection has fallen
dramatically. This fall has created new inequalities which
need to be addressed to protect vulnerable individuals
from infection and to maximise the overall population
benefit. Failing to address inequalities in access to care
for newly-arrived Asian-born MSM and other individ-
uals who are not eligible for Australia’s universal health
care insurance scheme Medicare may lead to ongoing
high rates of HIV transmission in this subpopulation
and the wider community. This may threaten Australia’s
international reputation as a safe country to visit, work
and study.
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